{
    "clinical_study": {
        "@rank": "31885", 
        "arm_group": [
            {
                "arm_group_label": "gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "gemcitabine 1000mg/m2\uff0cd1\uff0cd8\uff0cQ3W"
            }, 
            {
                "arm_group_label": "observation group", 
                "arm_group_type": "Other", 
                "description": "observation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to Evaluate and compare safety and efficacy of Gemcitabine\n      Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined\n      With Platinum Based First-line Chemotherapy"
        }, 
        "brief_title": "Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u226518 years\n\n          2. PS=0,1,2\n\n          3. Patients who were diagnosed by the histologic, cytologic diagnosis of extensive small\n             cell lung cancer\n\n          4. Patients received  Etoposide combined with platinum based first-line chemotherapy 6\n             cycles and there is evidence show the patent is PR/CR/SD\n\n          5. Expected lifetime>12 weeks\n\n          6. Signed written informed consent\n\n        Exclusion Criteria:\n\n        Small cell lung cancer non small cell hybrid Women during pregnancy or lactation\n        previously treated with two or more than two kinds of treatment Any non remission of\n        >CTCAE caused tumor treatment past grade 2 toxicity Ccr<30 ml/min (calculated by\n        Cockcroft-Gault formula) hepatic insufficiency\uff1a\n\n          1. Tbil> 1.5\u00d7ULN\n\n          2. ALT and AST > 2.5\u00d7ULN (Patients with liver metastasis>5\u00d7ULN) Alkaline phosphatase\uff1e2.5\n             \u00d7ULN(Patients with liver metastasis>5\u00d7ULN)\n\n          3. Severe symptomatic heart disease\n\n          4. Symptomatic brain metastases\n\n          5. In the last 5 years have been or are suffering from other histological types of\n             malignant tumor\n\n          6. There are serious or uncontrolled systemic diseases\n\n          7. During the study period planned radiotherapy on target lesion\n\n          8. During the study period, plans to use other antineoplastic therapy\n\n          9. Clinical study on treatment of 30 days beginning period prior to participate in any\n             study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039518", 
            "org_study_id": "WXH-gemcitabine-SCLC"
        }, 
        "intervention": [
            {
                "arm_group_label": "gemcitabine", 
                "description": "gemcitabine 1000mg/m2\uff0cd1\uff0cd8\uff0cQ3W", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "gemcitabine 1000mg/m2\uff0cd1\uff0cd8\uff0cQ3W"
            }, 
            {
                "arm_group_label": "observation group", 
                "description": "observation group", 
                "intervention_name": "observation group", 
                "intervention_type": "Other", 
                "other_name": "observation group"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Progression free Survival", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "xhwu2011@yahoo.com", 
                "last_name": "Wu X hua, doctor", 
                "phone": "13482888167"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy", 
        "overall_contact": {
            "email": "xhwu2011@yahoo.com", 
            "last_name": "Wu X Hua, doctor", 
            "phone": "13482888167"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "WU X HUA, DOCTOR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039518"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xianghua Wu", 
            "investigator_title": "Associate Chief Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}